Oxford BioDynamics PLC Notice of Results (0248A)
27 May 2021 - 6:00PM
UK Regulatory
TIDMOBD
RNS Number : 0248A
Oxford BioDynamics PLC
27 May 2021
27 May 2021
Oxford BioDynamics Plc
( "OBD" or the "Company" and, together with its subsidiaries,
the "Group")
Notice of Interim Results
Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology
company developing precision medicine tests for personalized
healthcare based on the EpiSwitch(R) 3D genomics platform, expects
to announce its interim results for the half-year ended 31 March
2021 on 15 June 2021.
-Ends-
For further details please contact:
Oxford BioDynamics Plc Tel: +44 (0)1865
Jon Burrows, CEO 518910
Paul Stockdale, CFO
Shore Capital - Nominated Adviser and Tel: +44 (0)20
Broker 7408 4090
Advisory: Edward Mansfield / John More
Broking: Fiona Conroy
Instinctif Partners Tel: +44 (0)20
Melanie Toyne-Sewell / Agnes Stephens 7457 2020
/ OxfordBioDynamics@instinctif.com
Katie Duffell / Nathan Billis
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology
company, advancing personalized healthcare by developing and
commercializing precision medicine tests for life-changing
diseases.
The Company has developed a proprietary 3D genomic biomarker
platform, EpiSwitch(R), which can build molecular diagnostic
classifiers for prediction of response to therapy, patient
prognosis, disease diagnosis and subtyping, and residual disease
monitoring in a wide range of indications.
In March 2021, the Company launched its first commercial
prognostic test, EpiSwitch (R) CST (Covid Severity Test) and the
first commercially available microarray kit for high-resolution 3D
genome profiling and biomarker discovery, EpiSwitch(R) Explorer
Array Kit . Its next product will be a predictive immune response
profile for immuno-oncology (IO) checkpoint inhibitor treatments,
to be launched later in 2021.
Oxford BioDynamics has participated in more than 40 partnerships
with big pharma and leading institutions including Pfizer, EMD
Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts
General Hospital and Mitsubishi Tanabe Pharma.
The Company has created a valuable technology portfolio,
including biomarker arrays, molecular diagnostic tests,
bioinformatic tools for 3D genomics and an expertly curated 3D
genome knowledgebase comprising hundreds of millions of data points
from over 10,000 samples in more than 30 human diseases.
OBD is headquartered in Oxford, UK and is listed on AIM of the
London Stock Exchange. It also has a commercial team in the US and
a reference laboratory in Penang, Malaysia
For more information, please visit the Company's website ,
www.oxfordbiodynamics.com , or follow on Twitter or LinkedIn .
About EpiSwitch(R)
The 3D configuration of the genome plays a crucial role in gene
regulation. By mapping this architecture and identifying abnormal
configurations, EpiSwitch(R) can be used to diagnose patients or
determine how individuals might respond to a disease or
treatment.
Built on over 10 years of research, EpiSwitch(R) is Oxford
Biodynamics' award-winning, proprietary platform that enables
screening, evaluation, validation and monitoring of 3D genomic
biomarkers. The technology is fully developed, based on testing of
over 10,000 samples in 30 disease areas, and reduced to
practice.
In addition to stratifying patients with respect to anticipated
clinical outcome, EpiSwitch(R) data offer insights into systems
biology and the physiological manifestation of disease that are
beyond the scope of other molecular modalities. The technology has
performed well in academic medical research settings and has been
validated through its integration in biomarker discovery and
clinical development with big pharma.
Oxford BioDynamics is leveraging its technology to develop a
pipeline of tests in a wide range of indications, such as
immuno-oncology, neurodegenerative and autoimmune diseases, to
follow its commercial EpiSwitch (R) CST (Covid Severity Test).
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORDDLBLFELEBBX
(END) Dow Jones Newswires
May 27, 2021 04:00 ET (08:00 GMT)
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From May 2023 to May 2024